Stay updated on ARCHES-2 Study: ARO-ANG3 Clinical Trial
Sign up to get notified when there's something new on the ARCHES-2 Study: ARO-ANG3 Clinical Trial page.

Latest updates to the ARCHES-2 Study: ARO-ANG3 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a new site revision note: Revision: v3.4.2 was added, with v3.4.1 retained for context. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center status with a link to opm.gov for updates. Updated the site revision to v3.4.1, replacing the previous v3.4.0.SummaryDifference0.3%

- Check28 days agoChange DetectedGlossary is now shown by default, and QA metadata such as 'Last Update Submitted that Met QC Criteria' and 'Last Update Posted' are displayed with a new 'Revision: v3.4.0' banner. The No FEAR Act Data label was added and the previous 'No FEAR Act data' label and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added to the page and Revision: v3.3.3 was removed. This appears to be a minor metadata update that does not modify the study details, endpoints, or eligibility criteria.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a comprehensive list of study locations across multiple regions (California, Florida, Minnesota, Nebraska, Nevada, New York, North Carolina, Ohio, Pennsylvania, Texas; New South Wales, Queensland; Ontario, Quebec) under Locations. Updated the revision tag from v3.3.2 to v3.3.3 and removed the prior version indicator.SummaryDifference1%

- Check78 days agoChange DetectedThe ARCHES-2 study record adds many new research sites worldwide and updates open-label extension timepoints and additional lipid endpoints.SummaryDifference2%

Stay in the know with updates to ARCHES-2 Study: ARO-ANG3 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARCHES-2 Study: ARO-ANG3 Clinical Trial page.